OncoMatch/Clinical Trials/NCT07134842

A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

Is NCT07134842 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Ipilimumab (3 mg/kg) for glioblastoma.

Phase 1RecruitingUniversity College, LondonNCT07134842Data as of May 2026

Treatment: Ipilimumab (3 mg/kg) — WinGlio is a phase I study investigating neoadjuvant (before surgery) ipilimumab ( a type of immunotherapy drug) in patients with newly diagnosed glioblastoma (a form of brain cancer). Participants will receive up to 2 cycles of ipilimumab prior to the standard of care treatments for this patient group which can include debulking surgery and chemoradiation. The aim of giving the ipilimumab to the participants is to see if it is safe to treat patients with this condition with ipilimumab and also to see if the drug helps to reduce or control the patient's disease.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any treatment for glioblastoma other than biopsy or limited resection

Exception: biopsy or limited resection leaving residual disease

Prior treatment for glioblastoma other than a biopsy or limited resection leaving residual disease

Lab requirements

Blood counts

Hb ≥9 g/dL; Neutrophils ≥1.5 x 10^9/L; Platelets ≥100 x 10^9/L; Lymphocyte count ≥1.0 x 10^9/L

Kidney function

Creatinine clearance of ≥ 50mL/min calculated by Cockroft-Gault equation

Liver function

Bilirubin ≤ 1.5 x ULN (except for patients with known Gilbert's Syndrome who may have total bilirubin ≤ 3 x ULN); AST or ALT ≤ 2.5 x ULN

Adequate organ and bone marrow function: Hb ≥9 g/dL, Neutrophils ≥1.5 x 10^9/L, Platelets ≥100 x 10^9/L, Lymphocyte count ≥1.0 x 10^9/L; Adequate renal function: Creatinine clearance of ≥ 50mL/min calculated by Cockroft-Gault equation; Adequate liver function: Bilirubin ≤ 1.5 x ULN (except for patients with known Gilbert's Syndrome who may have total bilirubin ≤ 3 x ULN); AST or ALT ≤ 2.5 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify